(Q37551901)

21 August 2017

1 reference

title

Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine (English)

1 reference

21 August 2017

1 reference

personalized medicine

1 reference

Felix W Frueh

1

1 reference

21 August 2017

publication date

1 July 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

7

1 reference

21 August 2017

page(s)

1077-1081

1 reference

Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease

21 August 2017

cites work

1 reference

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

21 January 2018

1 reference

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

21 January 2018

1 reference

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

Pharmacogenetics--tailoring treatment for the outliers

21 January 2018

1 reference

Warfarin and pharmacogenomic testing: what would Pascal do?

21 January 2018

1 reference

HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome.

21 January 2018

1 reference

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

21 January 2018

1 reference

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect".

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.09.62

1 reference

21 August 2017

1 reference